Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Published:2018-01-13 Issue:3 Volume:103 Page:378-383
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Nayak Satyaprakash¹,Sander Oliver²,Al-Huniti Nidal³,de Alwis Dinesh⁴,Chain Anne⁴,Chenel Marylore⁵,Sunkaraneni Soujanya⁶,Agrawal Shruti⁷,Gupta Neeraj⁸,Visser Sandra A.G.⁹

Affiliation:

1. Pfizer; Cambridge Massachusetts USA

2. Novartis Pharma AG; Basel Switzerland

3. Quantitative Clinical Pharmacology; AstraZeneca; Waltham Massachusetts USA

4. MSD; Rahway New Jersey USA

5. Servier, Clinical Pharmacokinetics and Pharmacometrics; Suresnes France

6. Sunovion; Marlborough Massachusetts USA

7. Bristol-Myers Squibb; Lawrenceville New Jersey USA

8. Millennium Pharmaceuticals, Inc.; Cambridge Massachusetts USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

9. GSK, King of Prussia; Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference5 articles.

1. Model-based drug development: the road to quantitative pharmacology;Zhang;J. Pharmacokinet. Pharmacodyn.,2006

2. Good practices in model-informed drug discovery and development (MID3): practice, application and documentation. EFPIA MID3 workgroup;Marshall;CPT Pharmacodynamics Syst. Pharmacol.,2016

3. Model-based drug development: a rational approach to efficiently accelerate drug development;Milligan;Clin. Pharmacol. Ther.,2013

4. Impact of modeling and simulation: myth or fact?;Allerheiligen;Clin. Pharmacol. Ther.,2014

5. Common best practice in modeling & simulation across quantitative disciplines: a comparison of independently emerging proposals;Visser;Stat. Biopharm. Res.,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative research methodologies in the EU regulatory framework: an analysis of EMA qualification procedures from a pediatric perspective;Frontiers in Medicine;2024-03-28

2. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma;CPT: Pharmacometrics & Systems Pharmacology;2023-08-02

3. Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study;Expert Opinion on Investigational Drugs;2023-06-29

4. Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions;Frontiers in Pharmacology;2022-06-08

5. Stably Accelerating Stiff Quantitative Systems Pharmacology Models: Continuous-Time Echo State Networks as Implicit Machine Learning;IFAC-PapersOnLine;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3